Status: current, Defined. Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3769837014 | Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
3769838016 | Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | en | Synonym | Active | Case insensitive | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has unit of presentation | Tablet | true | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has manufactured dose form | Orodispersible tablet | true | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Is a | Carbidopa and levodopa only product in oromucosal dose form | false | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength numerator value | 100 | false | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has BoSS | Levodopa | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has precise active ingredient | Carbidopa | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has BoSS | Carbidopa anhydrous | true | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has presentation strength numerator value | 25 | false | Inferred relationship | Some | 2 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Has precise active ingredient | Levodopa | true | Inferred relationship | Some | 1 | |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Some | ||
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg orodispersible tablet | Is a | Carbidopa and levodopa only product in oral dose form | true | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets